Cargando…

Efectividad e impacto económico de un programa de atención integrada con soporte de telemedicina a pacientes diabéticos tipo 2 tratados con insulina (estudio GITDIABE)

AIM: To evaluate if insulin-treated type 2 diabetic patients with blood glucose self-monitoring (DIA), included in a program of integrated management of diabetes mellitus (DM), achieve a better level of metabolic control with telemedicine support than with conventional support, after 12 months follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoriza, Jose M., Ibañez, Annabel, Pérez-Berruezo, Xavier, Inoriza-Nadal, Cristina, Coderch, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876025/
https://www.ncbi.nlm.nih.gov/pubmed/27423246
http://dx.doi.org/10.1016/j.aprim.2016.04.004
_version_ 1783473137565827072
author Inoriza, Jose M.
Ibañez, Annabel
Pérez-Berruezo, Xavier
Inoriza-Nadal, Cristina
Coderch, Jordi
author_facet Inoriza, Jose M.
Ibañez, Annabel
Pérez-Berruezo, Xavier
Inoriza-Nadal, Cristina
Coderch, Jordi
author_sort Inoriza, Jose M.
collection PubMed
description AIM: To evaluate if insulin-treated type 2 diabetic patients with blood glucose self-monitoring (DIA), included in a program of integrated management of diabetes mellitus (DM), achieve a better level of metabolic control with telemedicine support than with conventional support, after 12 months follow-up. The impact on the use and cost of healthcare services, pharmaceutical expenditure, and consumption of test strips for blood glucose, was also assessed. DESIGN: A prospective parallel cohorts study. FIELD: Four basic health areas of an integrated healthcare organisation. PARTICIPANTS: The study included 126 DIA patients aged 15 or more years, treated with rapid or intermediate Insulin and blood glucose self-monitoring, grouped into 42 cases and 84 controls, matched according to age, sex, level of metabolic control, and morbidity profile. INTERVENTION: Telematics physician-patient communication and download of blood glucose self-monitoring data through the Emminens eConecta(®) platform; test strips home delivered according to consumption. Hidden controls with usual follow-up. MAIN MEASUREMENTS: Glycosylated haemoglobin (%HbA1c); perception of quality of life (EuroQol-5 and EsDQOL); cardiovascular risk; use of healthcare resources; consumption of test strips; pharmaceutical and healthcare expenditure. RESULTS: Reduction of 0.38% in HbA1c in the cases (95% CI:−0.89% to 0.12%). No significant differences with regard to any of the activities registered, or any significant change in the quality of life. CONCLUSIONS: The results obtained are similar to other equivalent studies. The profile of the patient is elderly and with multiple morbidities, who still have technological limitations. To surpass these barriers, it would be necessary to devote more time to the training and to the resolution of possible technological problems.
format Online
Article
Text
id pubmed-6876025
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-68760252019-11-26 Efectividad e impacto económico de un programa de atención integrada con soporte de telemedicina a pacientes diabéticos tipo 2 tratados con insulina (estudio GITDIABE) Inoriza, Jose M. Ibañez, Annabel Pérez-Berruezo, Xavier Inoriza-Nadal, Cristina Coderch, Jordi Aten Primaria Originales AIM: To evaluate if insulin-treated type 2 diabetic patients with blood glucose self-monitoring (DIA), included in a program of integrated management of diabetes mellitus (DM), achieve a better level of metabolic control with telemedicine support than with conventional support, after 12 months follow-up. The impact on the use and cost of healthcare services, pharmaceutical expenditure, and consumption of test strips for blood glucose, was also assessed. DESIGN: A prospective parallel cohorts study. FIELD: Four basic health areas of an integrated healthcare organisation. PARTICIPANTS: The study included 126 DIA patients aged 15 or more years, treated with rapid or intermediate Insulin and blood glucose self-monitoring, grouped into 42 cases and 84 controls, matched according to age, sex, level of metabolic control, and morbidity profile. INTERVENTION: Telematics physician-patient communication and download of blood glucose self-monitoring data through the Emminens eConecta(®) platform; test strips home delivered according to consumption. Hidden controls with usual follow-up. MAIN MEASUREMENTS: Glycosylated haemoglobin (%HbA1c); perception of quality of life (EuroQol-5 and EsDQOL); cardiovascular risk; use of healthcare resources; consumption of test strips; pharmaceutical and healthcare expenditure. RESULTS: Reduction of 0.38% in HbA1c in the cases (95% CI:−0.89% to 0.12%). No significant differences with regard to any of the activities registered, or any significant change in the quality of life. CONCLUSIONS: The results obtained are similar to other equivalent studies. The profile of the patient is elderly and with multiple morbidities, who still have technological limitations. To surpass these barriers, it would be necessary to devote more time to the training and to the resolution of possible technological problems. Elsevier 2017-03 2016-08-08 /pmc/articles/PMC6876025/ /pubmed/27423246 http://dx.doi.org/10.1016/j.aprim.2016.04.004 Text en © 2016 Elsevier España, S.L.U. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Originales
Inoriza, Jose M.
Ibañez, Annabel
Pérez-Berruezo, Xavier
Inoriza-Nadal, Cristina
Coderch, Jordi
Efectividad e impacto económico de un programa de atención integrada con soporte de telemedicina a pacientes diabéticos tipo 2 tratados con insulina (estudio GITDIABE)
title Efectividad e impacto económico de un programa de atención integrada con soporte de telemedicina a pacientes diabéticos tipo 2 tratados con insulina (estudio GITDIABE)
title_full Efectividad e impacto económico de un programa de atención integrada con soporte de telemedicina a pacientes diabéticos tipo 2 tratados con insulina (estudio GITDIABE)
title_fullStr Efectividad e impacto económico de un programa de atención integrada con soporte de telemedicina a pacientes diabéticos tipo 2 tratados con insulina (estudio GITDIABE)
title_full_unstemmed Efectividad e impacto económico de un programa de atención integrada con soporte de telemedicina a pacientes diabéticos tipo 2 tratados con insulina (estudio GITDIABE)
title_short Efectividad e impacto económico de un programa de atención integrada con soporte de telemedicina a pacientes diabéticos tipo 2 tratados con insulina (estudio GITDIABE)
title_sort efectividad e impacto económico de un programa de atención integrada con soporte de telemedicina a pacientes diabéticos tipo 2 tratados con insulina (estudio gitdiabe)
topic Originales
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876025/
https://www.ncbi.nlm.nih.gov/pubmed/27423246
http://dx.doi.org/10.1016/j.aprim.2016.04.004
work_keys_str_mv AT inorizajosem efectividadeimpactoeconomicodeunprogramadeatencionintegradaconsoportedetelemedicinaapacientesdiabeticostipo2tratadosconinsulinaestudiogitdiabe
AT ibanezannabel efectividadeimpactoeconomicodeunprogramadeatencionintegradaconsoportedetelemedicinaapacientesdiabeticostipo2tratadosconinsulinaestudiogitdiabe
AT perezberruezoxavier efectividadeimpactoeconomicodeunprogramadeatencionintegradaconsoportedetelemedicinaapacientesdiabeticostipo2tratadosconinsulinaestudiogitdiabe
AT inorizanadalcristina efectividadeimpactoeconomicodeunprogramadeatencionintegradaconsoportedetelemedicinaapacientesdiabeticostipo2tratadosconinsulinaestudiogitdiabe
AT coderchjordi efectividadeimpactoeconomicodeunprogramadeatencionintegradaconsoportedetelemedicinaapacientesdiabeticostipo2tratadosconinsulinaestudiogitdiabe
AT efectividadeimpactoeconomicodeunprogramadeatencionintegradaconsoportedetelemedicinaapacientesdiabeticostipo2tratadosconinsulinaestudiogitdiabe